The death rate for patients with takotsubo syndrome is comparable with that of those with myocardial infarction, with cardiovascular conditions being the most common cause of death.
Filling an evidence gap, a pooled analysis of patients with heart failure across the LVEF spectrum supports starting sacubitril-valsartan in the hospital.
In the randomized trial QUEST trial, a traditional Chinese medicine called qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in HFrEF.
Sacubitril-valsartan led to a greater reduction of natriuretic peptides, less worsening renal function, but a higher rate of hypotension compared with valsartan in PARAGLIDE-HF.
A new study shows significant variation in the blood pressure response to various antihypertensive medications between individuals, raising the possibility of future personalized therapy.